Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Gl

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Related Keywords

Sweden , Stockholm , , G Steering Committee Member David Kavanagh , Novartis , European Renal Association Congress , Foundation Trust David Kavanagh , Faculty Of Medical Sciences At Newcastle University , David Kavanagh , Steering Committee Member David Kavanagh , Complement Therapeutics , Honorary Consultant Nephrologist , Medical Sciences , European Renal Association ,